Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme
A phase 2 trial of Entrectinib in colorectal cancer and melanoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is a phase 2 interventional study registered as NCT02568267 by Hoffmann-La Roche, with 534 participants enrolled, started 2015-11-19 and due to reach its primary completion in 2027-06-30. Interventions recorded: Entrectinib. Conditions listed: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C
Shares Entrectinib, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Shares Entrectinib, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares Entrectinib, Non-small-cell lung cancer.
- TrialA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.